Differential effects of 5-hydroxytryptamine4 receptor agonists at gastric versus cardiac receptors: an operational framework to explain and quantify organ-specific behavior.
about
Current developments in pharmacological therapeutics for chronic constipationPrucalopride for constipation.Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disordersPredominant mucosal expression of 5-HT₄(+h) receptor splice variants in pig stomach and colon.A comparison of the pharmacological properties of guinea-pig and human recombinant 5-HT4 receptors.Effect of prucalopride on the pharmacokinetics of oral contraceptives in healthy women.Selective desensitization of the 5-HT4 receptor-mediated response in pig atrium but not in stomach.Prucalopride: a new drug for the treatment of chronic constipation.Behavioural and new pharmacological treatments for constipation: getting the balance rightPharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome.New treatment options for chronic constipation: mechanisms, efficacy and safety.Influence of a new 5-HT4 receptor partial agonist, YKP10811, on visceral hypersensitivity in rats triggered by stress and inflammation.Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans.5-HT4 receptors facilitate cholinergic neurotransmission throughout the murine gastrointestinal tract.Synergy between 5-HT4 receptor stimulation and phosphodiesterase 4 inhibition in facilitating acetylcholine release in human large intestinal circular muscle.
P2860
Q27025474-35E25F5A-B3C2-4834-9991-73C5FA51F11CQ34094831-277EB58B-0CFB-48AF-B583-A86674921F7CQ34166903-DB521E0B-D019-46D4-AC3F-4E710D64C961Q34804110-C26F2F83-3648-427F-8960-CFF2BEA0002CQ36052511-3FB70805-6AE1-4BC5-BCA1-915D212AE074Q36767729-B7E9B300-2ECF-4F6A-8233-41ADD947838DQ37231016-BED3B4B6-57D7-449F-BEF1-27EB91FF801EQ37578493-4C9AA057-28E0-4BB3-96EB-9FC3A18E0740Q37783838-0D55BF8F-AF7E-47BC-B10D-119B36545C7AQ37954521-54B071C0-3820-4863-8111-9A9A76119ED3Q37960501-55169EB2-1B0E-4F9B-8ECF-90D528A68415Q42703872-40501EA8-DB8D-470B-90B7-061741E963B1Q43342449-742CDA6E-6023-4CDD-A9A1-716461F57B8BQ46398936-4EA8EA92-CBA4-4748-8723-7C823CC68CB2Q48254467-40B66A3D-7908-4BB9-987E-68BDA8E76174
P2860
Differential effects of 5-hydroxytryptamine4 receptor agonists at gastric versus cardiac receptors: an operational framework to explain and quantify organ-specific behavior.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Differential effects of 5-hydr ...... ntify organ-specific behavior.
@en
Differential effects of 5-hydr ...... ntify organ-specific behavior.
@nl
type
label
Differential effects of 5-hydr ...... ntify organ-specific behavior.
@en
Differential effects of 5-hydr ...... ntify organ-specific behavior.
@nl
prefLabel
Differential effects of 5-hydr ...... ntify organ-specific behavior.
@en
Differential effects of 5-hydr ...... ntify organ-specific behavior.
@nl
P2093
P356
P1476
Differential effects of 5-hydr ...... ntify organ-specific behavior.
@en
P2093
Jan A J Schuurkes
Joris H De Maeyer
Nicolaas H Prins
Romain A Lefebvre
P304
P356
10.1124/JPET.106.101329
P407
P577
2006-02-24T00:00:00Z